For millions of people with severe asthma, daily oral steroid pills are a lifeline—but they come with a steep hidden price. Michael Wechsler, director of the Cohen Family Asthma Institute at National Jewish Health, has watched patients struggle with the long-term consequences: diabetes, osteoporosis, cardiovascular disease, and the everyday burden of managing a treatment that can be as disabling as the disease itself. Now, new findings from the Phase III SUNRISE trial published in The Lancet Respiratory Medicine offer genuine hope that patients might escape this trap.
The trial tested tezepelumab, a monoclonal antibody therapy, in adults with severe asthma who depend on daily oral corticosteroids even while using high-dose inhaled treatments. What researchers found was striking: over just 28 weeks, patients given tezepelumab were nearly three times more likely than those receiving placebo to significantly reduce their steroid dependence while keeping their asthma under control.
The numbers tell a compelling story. Nearly seven in ten patients—69 percent—achieved at least a 50 percent reduction in their daily oral corticosteroid dose. But the most remarkable result came from the 35 percent of tezepelumab-treated patients who stopped oral steroids entirely, compared to just 21 percent in the placebo group. These weren't temporary improvements that faded once the trial ended; patients maintained asthma control throughout, meaning they weren't trading one problem for another.
"These findings are important because they show that patients with severe asthma treated with tezepelumab may be able to substantially reduce their dependence on oral steroids without sacrificing asthma control," Wechsler explained. For patients who have resigned themselves to a lifetime of daily steroid pills and their mounting side effects, that possibility represents something rare in medicine: a genuine exit route.
The SUNRISE trial was a rigorous, multicenter, double-blind, placebo-controlled study designed to answer a question that matters deeply to people living with severe asthma. Oral corticosteroids work, but they exact a toll. Beyond diabetes and bone loss, chronic use affects mental health, metabolism, and the simple confidence of knowing your body isn't being steadily reshaped by medication. The trial participants had already exhausted the standard playbook—they were on maximum inhaled therapy and still struggling. For them, tezepelumab offered something new.
What makes this breakthrough particularly meaningful is its timing. The field of severe asthma treatment has been evolving, but many patients still cycle through years of high-dose steroids waiting for the right biologic therapy to work. The SUNRISE results suggest that tezepelumab isn't just another option—it's a game-changer for the corticosteroid-dependent population specifically. The improvement isn't marginal: a threefold increase in the likelihood of substantial dose reduction is substantial in clinical terms.
The path forward is clear, even as questions remain about long-term outcomes and which patients respond best. For the hundreds of thousands of people with severe oral corticosteroid-dependent asthma worldwide, tezepelumab represents the possibility of reclaiming a life not built around daily steroid pills—and the freedom from their slow-accumulating costs.